U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Physician Preferred Medical, LLC - 07/28/2017
  1. Warning Letters

CLOSEOUT LETTER

Physician Preferred Medical, LLC

Recipient:
Physician Preferred Medical, LLC

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204 

 
 

July 28, 2017

Kenneth Ryan Orton, Owner
Physician Preferred Medical, LLC dba PPM Pharmacy
3300 NW 56th Street, Suite 101
Oklahoma City, OK 73112

Dear Mr. Orton:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (2016-DAL-WL-08) dated January 20, 2016. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
If you have additional questions, please contact me at 214-253-5288.

Sincerely,
/S/

John W. Diehl
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II 

Back to Top